Karisa C. Schreck, MD, PhD

Articles

Ongoing Research in Primary CNS Malignancies

December 10th 2025

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss ongoing research to watch in primary central nervous system tumors.

The FORTE Trial: Data for Plixorafenib in BRAF V600+ CNS Tumors

December 10th 2025

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss available data for plixorafenib in central nervous system tumors harboring BRAF V600 mutations from the FORTE trial.

Safety Considerations for BRAF Inhibition in CNS Malignancies

December 3rd 2025

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the safety profile and management of toxicities associated with BRAF inhibitors in central nervous system tumors.

Detailing the Exploration of Plixorafenib in CNS Malignancies

December 3rd 2025

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the novel BRAF inhibitor plixorafenib and its ongoing evaluation in central nervous system malignancies.

The Role of BRAF Inhibition in CNS Malignancies

November 24th 2025

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the use of BRAF inhibitors in the treatment of patients with central nervous system malignanices.

Current Treatment Standards in Primary CNS Malignancies

November 24th 2025

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss current treatment approaches in central nervous system malignancies.